Town & Country Bank & Trust CO dba First Bankers Trust CO Has $2.91 Million Holdings in Danaher Co. (NYSE:DHR)

Town & Country Bank & Trust CO dba First Bankers Trust CO decreased its holdings in Danaher Co. (NYSE:DHR) by 5.8% during the 1st quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 11,669 shares of the conglomerate’s stock after selling 725 shares during the quarter. Danaher accounts for approximately 1.2% of Town & Country Bank & Trust CO dba First Bankers Trust CO’s investment portfolio, making the stock its 27th biggest holding. Town & Country Bank & Trust CO dba First Bankers Trust CO’s holdings in Danaher were worth $2,914,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Cape Investment Advisory Inc. bought a new stake in Danaher during the fourth quarter worth $25,000. Tsfg LLC boosted its holdings in Danaher by 733.3% during the 1st quarter. Tsfg LLC now owns 100 shares of the conglomerate’s stock worth $25,000 after acquiring an additional 88 shares during the last quarter. BKM Wealth Management LLC bought a new stake in shares of Danaher in the 4th quarter worth $27,000. Wetzel Investment Advisors Inc. purchased a new stake in shares of Danaher in the fourth quarter valued at about $29,000. Finally, Rakuten Securities Inc. bought a new position in shares of Danaher during the fourth quarter valued at about $36,000. 79.05% of the stock is owned by institutional investors.

Insider Buying and Selling at Danaher

In other news, CEO Rainer Blair sold 9,005 shares of the firm’s stock in a transaction that occurred on Thursday, May 16th. The shares were sold at an average price of $265.00, for a total value of $2,386,325.00. Following the completion of the transaction, the chief executive officer now directly owns 106,990 shares in the company, valued at $28,352,350. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In related news, CEO Rainer Blair sold 9,005 shares of the company’s stock in a transaction that occurred on Thursday, May 16th. The shares were sold at an average price of $265.00, for a total transaction of $2,386,325.00. Following the sale, the chief executive officer now owns 106,990 shares of the company’s stock, valued at approximately $28,352,350. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Brian W. Ellis sold 4,000 shares of the firm’s stock in a transaction on Wednesday, April 24th. The shares were sold at an average price of $250.01, for a total transaction of $1,000,040.00. Following the completion of the transaction, the senior vice president now directly owns 29,830 shares of the company’s stock, valued at $7,457,798.30. The disclosure for this sale can be found here. Insiders sold 148,783 shares of company stock valued at $37,536,717 in the last quarter. 11.10% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on DHR. TD Cowen upped their price objective on shares of Danaher from $280.00 to $290.00 and gave the stock a “buy” rating in a research report on Wednesday, April 24th. StockNews.com downgraded Danaher from a “buy” rating to a “hold” rating in a research report on Tuesday, June 25th. Barclays raised their target price on Danaher from $260.00 to $270.00 and gave the company an “equal weight” rating in a research report on Wednesday, April 24th. Robert W. Baird increased their price target on shares of Danaher from $259.00 to $271.00 and gave the company an “outperform” rating in a research report on Wednesday, April 24th. Finally, Jefferies Financial Group initiated coverage on shares of Danaher in a research report on Monday, June 3rd. They issued a “buy” rating and a $295.00 price objective on the stock. Six equities research analysts have rated the stock with a hold rating and ten have given a buy rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $269.29.

Danaher Stock Performance

Shares of NYSE DHR traded down $1.64 during midday trading on Friday, hitting $249.85. The company’s stock had a trading volume of 4,638,276 shares, compared to its average volume of 3,371,169. The stock has a fifty day moving average price of $255.96 and a 200 day moving average price of $246.61. The firm has a market capitalization of $185.06 billion, a price-to-earnings ratio of 42.35, a P/E/G ratio of 3.82 and a beta of 0.85. Danaher Co. has a one year low of $182.09 and a one year high of $269.11. The company has a current ratio of 1.85, a quick ratio of 1.51 and a debt-to-equity ratio of 0.31.

Danaher (NYSE:DHR) last issued its earnings results on Tuesday, April 23rd. The conglomerate reported $1.92 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.72 by $0.20. Danaher had a net margin of 16.78% and a return on equity of 11.43%. The business had revenue of $5.80 billion for the quarter, compared to analysts’ expectations of $5.62 billion. During the same quarter in the previous year, the firm posted $2.36 EPS. The business’s revenue for the quarter was down 2.6% compared to the same quarter last year. On average, research analysts forecast that Danaher Co. will post 7.63 EPS for the current fiscal year.

Danaher Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, July 26th. Shareholders of record on Friday, June 28th will be paid a $0.27 dividend. The ex-dividend date of this dividend is Friday, June 28th. This represents a $1.08 annualized dividend and a yield of 0.43%. Danaher’s dividend payout ratio is currently 18.31%.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.